These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 18424792

  • 1. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
    Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF.
    J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
    [Abstract] [Full Text] [Related]

  • 2. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.
    Putnam SD, Sader HS, Moet GJ, Mendes RE, Jones RN.
    Diagn Microbiol Infect Dis; 2010 Aug; 67(4):359-68. PubMed ID: 20638605
    [Abstract] [Full Text] [Related]

  • 3. Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin.
    Mendes RE, Flamm RK, Farrell DJ, Sader HS, Jones RN.
    J Chemother; 2016 Apr; 28(2):83-8. PubMed ID: 26058844
    [Abstract] [Full Text] [Related]

  • 4. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009).
    Mendes RE, Sader HS, Farrell DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2012 Jan; 72(1):113-7. PubMed ID: 22078909
    [Abstract] [Full Text] [Related]

  • 5. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
    Sader HS, Watters AA, Fritsche TR, Jones RN.
    BMC Infect Dis; 2007 Apr 18; 7():29. PubMed ID: 17442104
    [Abstract] [Full Text] [Related]

  • 6. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
    Sader HS, Streit JM, Fritsche TR, Jones RN.
    Clin Microbiol Infect; 2006 Sep 18; 12(9):844-52. PubMed ID: 16882289
    [Abstract] [Full Text] [Related]

  • 7. Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
    Pfaller MA, Rhomberg PR, Sader HS, Mendes RE, Jones RN.
    J Chemother; 2010 Oct 18; 22(5):304-11. PubMed ID: 21123152
    [Abstract] [Full Text] [Related]

  • 8. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
    Gales AC, Sader HS, Jones RN.
    Clin Microbiol Infect; 2005 Feb 18; 11(2):95-100. PubMed ID: 15679482
    [Abstract] [Full Text] [Related]

  • 9. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA, Jones RN, Leeds JA, Denys G, Sader HS, Fritsche TR.
    J Antimicrob Chemother; 2006 May 18; 57(5):914-23. PubMed ID: 16549511
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
    Jansen WT, Verel A, Verhoef J, Milatovic D.
    Antimicrob Agents Chemother; 2007 Sep 18; 51(9):3420-4. PubMed ID: 17606689
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH, Liu CY, Lu JJ, King CH, Hsueh PR.
    J Antimicrob Chemother; 2009 Dec 18; 64(6):1226-9. PubMed ID: 19833635
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
    Fritsche TR, Sader HS, Stillwell MG, Jones RN.
    Diagn Microbiol Infect Dis; 2009 Apr 18; 63(4):440-6. PubMed ID: 19302928
    [Abstract] [Full Text] [Related]

  • 13. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
    Mendes RE, Sader HS, Jones RN.
    Int J Antimicrob Agents; 2010 Oct 18; 36(4):374-9. PubMed ID: 20598860
    [Abstract] [Full Text] [Related]

  • 14. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD.
    Int J Antimicrob Agents; 2007 Aug 18; 30(2):143-9. PubMed ID: 17531446
    [Abstract] [Full Text] [Related]

  • 15. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
    Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I, Turnidge JD.
    Diagn Microbiol Infect Dis; 2009 Dec 18; 65(4):404-13. PubMed ID: 19913683
    [Abstract] [Full Text] [Related]

  • 16. Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).
    Duncan LR, Sader HS, Smart JI, Flamm RK, Mendes RE.
    J Glob Antimicrob Resist; 2017 Sep 18; 10():271-276. PubMed ID: 28735051
    [Abstract] [Full Text] [Related]

  • 17. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.
    Mendes RE, Farrell DJ, Sader HS, Streit JM, Jones RN.
    Diagn Microbiol Infect Dis; 2015 Apr 18; 81(4):275-9. PubMed ID: 25618421
    [Abstract] [Full Text] [Related]

  • 18. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.
    King A, Phillips I, Kaniga K.
    J Antimicrob Chemother; 2004 May 18; 53(5):797-803. PubMed ID: 15028667
    [Abstract] [Full Text] [Related]

  • 19. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
    Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF.
    Antimicrob Agents Chemother; 2008 Jul 18; 52(7):2383-8. PubMed ID: 18443115
    [Abstract] [Full Text] [Related]

  • 20. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
    Fritsche TR, Kirby JT, Jones RN.
    Diagn Microbiol Infect Dis; 2004 Jul 18; 49(3):201-9. PubMed ID: 15246511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.